Displaying drugs 251 - 275 of 554 in total
LY-2334737
LY2334737 has been used in trials studying the treatment of Solid Tumor, Metastatic Tumor, and Malignant Solid Tumor.
Investigational
Matched Description: … Solid Tumor. ... LY2334737 has been used in trials studying the treatment of Solid Tumor, Metastatic Tumor, and Malignant …
IDD-1
Lipids promote the fusion of liposomes to cells. Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.
Investigational
Matched Description: … Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor …
Polaprezinc
Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. It was determined that polaprezinc may be effective in pressure ulcer treatment . A study in 2013 showed...
Experimental
Matched Categories: … Tumor Necrosis Factor Blockers …
Astegolimab
Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Investigational
Matched Categories: … Tumor Necrosis Factor Blockers …
Sabarubicin
Sabarubicin has been used in trials studying the treatment of Prostate Cancer, Testicular Germ Cell Tumor, and Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … , and Unspecified Adult Solid Tumor, Protocol Specific. ... Sabarubicin has been used in trials studying the treatment of Prostate Cancer, Testicular Germ Cell Tumor …
99mTc-14 F7 Mab
99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor effect after treatment with 99mTc 14F7 Mab.
Investigational
Matched Description: … Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor ... 99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. …
AG-858
AG-858 (autologous heat-shock protein 70 peptide vaccine) is
a recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity...
Investigational
Matched Description: … Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity ... and tumor-specific T cells in animal models. ... AG-858 (autologous heat-shock protein 70 peptide vaccine) is
a recombinant cancer vaccine made with tumor-derived …
Berzosertib
Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
Investigational
Matched Description: … , Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others. ... Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor …
Pilaralisib
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
Investigational
OXI-4503
OXI-4503 is investigated in clinical trials for treating cancer/tumors. OXI-4503 is a solid. OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. OXI-4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA). In addition, however, preclinical data demonstrates...
Investigational
Matched Description: … OXI-4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. ... infiltrates, to an orthoquinone chemical species that has direct cytotoxic effects on tumor cells. ... by oxidative enzymes (e.g., tyrosinase and peroxidases), which are elevated in many solid tumors and tumor …
WX-UK1
WX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs. In animal models, WX-UK1 blocks tumor cell invasion, metastasis and primary tumor growth by inhibiting serine proteases and the urokinase Plasminogen Activator (uPA) system, which have been shown to play a key role in metastasis...
Investigational
Matched Description: … In animal models, WX-UK1 blocks tumor cell invasion, metastasis and primary tumor growth by inhibiting ... Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, ... Plasminogen Activator (uPA) system, which have been shown to play a key role in metastasis and primary tumor …
AP5346
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
IMA901
IMA901 is a vaccine consists of tumor-associated peptides (TUMAPs).
Investigational
Matched Description: … IMA901 is a vaccine consists of tumor-associated peptides (TUMAPs). …
Tesevatinib
Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.
Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs,...
Investigational
Matched Description: … demonstrated potent inhibition of tumor growth and causes tumor regression. ... tumor vascularization (blood vessel formation). ... Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and …
Ulocuplumab
Ulocuplumab is under investigation in Solid Tumor.
Investigational
Matched Description: … Ulocuplumab is under investigation in Solid Tumor. …
Linsitinib
An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.
Investigational
Matched Description: … proliferation and the induction of tumor cell apoptosis. ... IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell …
Cintredekin besudotox
Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual infiltrating glioblastoma multiforme (GBM) after tumor resection. Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, Pseudomonas...
Investigational
Matched Description: … The IL13 portion binds to receptors on the tumor. ... Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by ... CED) directly to brain tissue at risk for residual infiltrating glioblastoma multiforme (GBM) after tumor …
OBP-801
OBP-801 has been used in trials studying the treatment of Solid Tumor.
Investigational
Matched Description: … OBP-801 has been used in trials studying the treatment of Solid Tumor. …
ATG-101
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Matched Description: … immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. ... binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor …
IRL-1620
SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemotherapy.
Investigational
Matched Description: … of anticancer agents to the tumor. ... In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery …
Corticorelin acetate
Corticorelin acetate has been investigated for the treatment of Brain Edema and Brain Tumor.
Investigational
Matched Description: … Corticorelin acetate has been investigated for the treatment of Brain Edema and Brain Tumor. …
Bioymifi
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
Matched Description: … Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053] ... Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL …
Displaying drugs 251 - 275 of 554 in total